The University of Chicago Header Logo

Connection

James J. Dignam to Cetuximab

Back to Details
This is a "connection" page, showing publications James J. Dignam has written about Cetuximab.
James J. Dignam
Connection Strength
0.162
Cetuximab
  1. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. Lancet. 2019 01 05; 393(10166):40-50.
    View in: PubMed
    Score: 0.162
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.